Uptake of Aortic $^{18}$F-FDG Is Correlated with Low-Density Lipoprotein Cholesterol and Leptin in a General Population

Ai Haraguchi$^{1,2}$, Naomi Hayashida$^1$, Toshihiko Kamasaki$^{1,5}$, Izumi Miyamoto$^5$, Toshiya Usui$^5$, Takao Ando$^2$, Norio Abiru$^2$, Hironori Yamashita$^4$, Kenya Chiba$^5$, Takashi Kudo$^3$, Atsushi Kawakami$^2$, Noboru Takamura$^1$*

$^1$ Department of Global Health, Medicine and Welfare, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, $^2$ Department of Endocrinology and Metabolism, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, $^3$ Radioisotope Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, $^4$ Center for Health and Community Medicine, Nagasaki University, Nagasaki, Japan, $^5$ Nishi-Isahaya Hospital PET/CT Diagnostic Imaging Center, Isahaya, Japan

Abstract

**Objective:** This study investigated the relationship between aortic $^{18}$F-fluoro-2-deoxy-D-glucose ($^{18}$F-FDG) uptake and clinical and laboratory findings related to atherosclerosis in a general population.

**Methods:** $^{18}$F-FDG uptake in the ascending aorta was measured on the positron emission tomography/computed tomography (PET/CT) scans of 211 Japanese adults. The maximum target-to-background ratio (TBR) was compared with clinical and laboratory atherosclerosis findings.

**Results:** By multivariate regression analysis adjusted for age and sex, TBR-ascending aorta (TBR-A) was significantly correlated with various clinical and laboratory parameters, such as body mass index, log visceral fat area, low-density lipoprotein cholesterol (LDL-C), log fasting immunoreactive insulin, log homeostasis model assessment of insulin resistance, log total adiponectin and log-leptin, in all subjects. Furthermore, by multivariate linear regression analysis adjusted for confounding factors, TBR-A was significantly correlated with LDL-C ($\beta = 0.001$, $p = 0.03$) and log-leptin ($\beta = 0.336$, $p < 0.01$) in all subjects.

**Conclusion:** TBR-A was significantly correlated with LDL-C and log-leptin independent from confounding factors. Our results suggest that aortic $^{18}$F-FDG uptake is a good marker of atherosclerosis, even in a general population.

Introduction

Atherosclerotic diseases such as coronary heart disease and cerebrovascular disease are the leading cause of illness and death worldwide [1]. Although controlling risk factors such as smoking, blood pressure, and serum lipid levels [2] to reduce atherothrombotic events is recommended, a fifth of all cardiovascular events occur in individuals with no identifiable traditional risk factors [3]. Recently, atherosclerosis has been recognized as an inflammatory disease [4]. It is well known that plaque composition and biologic activity contribute significantly to the risk of vascular events [5,6]; however, since angiography is invasive for the evaluation of atherosclerosis, plaque inflammation and vulnerability cannot be directly observed [7].

Collectively, adipose tissue can be perceived a large gland that produces adipokines. Some studies have suggested that inflammation and dysfunction of adipose tissue in obesity may induce abnormal production of adipokines and result in the higher incidence of cardiovascular diseases among obese people [8]. Adipokines such as leptin and adiponectin play important roles in the metabolic regulation of obesity and obesity-related complications.

Leptin is mainly produced by white adipose tissue [9] and its production is regulated by energy level, food intake, several hormones, and various inflammatory mediators [10]. Leptin also provides the functional link between the immune system and energy homeostasis [11]. Hyperleptinemia in the general population is associated with atherosclerosis, hypertension, and metabolic syndrome [10]. Increased serum concentrations of leptin are also associated with an increased risk of myocardial infarction and stroke, independent of obesity and other traditional cardiovascular risk factors [12].
Aortic 18F-FDG Is Correlated with LDL-C and Leptin

1.3. 18F-FDG-PET/CT imaging

The PET/CT imaging study was performed with a PET/CT scanner (Discovery ST; GE Healthcare, Milwaukee, Wisconsin, USA). Details of this procedure have been described elsewhere [23–25]. In brief, imaging was started 50 min after intravenous injection of 18F-FDG through an anterior cubital vein. Injected 18F-FDG doses were determined according to each subject’s weight (4 MBq/kg); individual doses ranged from 146.2–403.9 MBq. The patients fasted for at least 6 h before 18F-FDG injection, and the glucose level of each participant was measured using a simple method before 18F-FDG injection. All participants showed glucose levels lower than 11.10 mmol/L (3.66–8.94). Each participant was scanned in the supine position with his or her arms placed alongside the body. The image acquisition time was 2.5 min per bed position. There were 7–8 bed positions, which allowed scanning of the entire body in a three-dimensional mode. The acquisition parameters for dual-detector helical CT were 140 kV, 30 mA, 3.75-mm slice thickness, and a pitch of 1.5. Attenuation correction was performed with acquired CT data. The PET/CT images displayed as coronal, sagittal, and transaxial slices were viewed on dedicated Workstation (Xeleris, GE Healthcare) [23].

1.4. Image Analysis

The PET and CT images of each participant were analyzed using a dedicated image analyzing software on a personal computer. The PET and CT images were superimposed to form a fused PET/CT image using the program. For the index of glucose metabolic activity in the common carotid arteries and ascending aorta, we calculated standardized uptake values (SUVs) of 18F-FDG in each region of interest (ROI). The ROIs of the common carotid arteries were obtained from 10 consecutive tomographic slices, beginning from the merging point with the carotid bifurcation [20]. The ROIs of the ascending aorta were also obtained from 10 consecutive tomographic slices, beginning from the merging point with the aortic arch. Maximum SUVs were obtained from each ROI. Blood-pool activity was measured by placing a circular ROI in the mid lumen of the superior vena cava on two different tomographic slices and then averaging the values to obtain the background SUV. The maximum SUVs of each arterial segment were averaged for both carotid arteries and the ascending aorta, and were then divided by the background SUV to yield maximum target-to-background ratios (TBR) for each patient [26] (Figure 1).

Prior to the analysis, we evaluated the correlation between TBR-ascending aorta (TBR-A) and other TBRs, such as TBR-right common carotid artery, TBR-left common carotid artery, TBR-right carotid bifurcation, and TBR-left carotid bifurcation, in 60 randomly selected subjects. We confirmed high correlations (r = 0.64, p < 0.01 vs. TBR-right common carotid artery, r = 0.65, p < 0.01 vs. TBR-left common carotid artery, r = 0.60, p < 0.01 vs. TBR-right carotid bifurcation and r = 0.59, p < 0.01 vs. TBR-left carotid bifurcation). Based on these results, TBR-A was used for analysis in this study.

1.5. Statistical Analysis

Results are expressed as mean ± standard deviation (SD). Differences in continuous variables between men and women were compared using the Mann-Whitney U test, and differences between categorized values were evaluated using the χ²-test. As visceral fat area, TG, IRI, HOMA-IR, 1.5-AG, HMW-A, T-A, leptin, and hs-CRP showed a skewed distribution, logarithmic transformation was performed for multivariate linear regression analysis. Simple correlations of TBR-A with other variables were
Subjects had a mean age (±SD) of 54.4±0.9 years (range, 34–75 years) in 119 men. For the 92 women, the mean age was 56.5±10.9 years (range, 33–87 years) (p = 0.39). TBR-A of men (1.74±0.39) was significantly higher than that of women (1.54±0.20) (p<0.01).

Table 2 shows the correlation coefficients of TBR-A with other variables as determined by univariate regression analysis. TBR-A was significantly correlated with BMI, waist circumference, visceral fat area, diastolic BP, FPG, TG, UA, Cr, IRI, HOMA-IR, HMW-A, T-A, and hs-CRP in all subjects. TBR-A was significantly correlated with BMI, IRI, HOMA-IR, and leptin in both men and women. Furthermore, TBR-A was significantly correlated with UA in men and waist circumference in women.

By multivariate regression analysis adjusted for age and sex, TBR-A was significantly correlated with BMI, waist circumference, log visceral fat area, diastolic BP, LDL-C, log TG, UA, Cr, log IRI, log HOMA-IR, log T-A, log-leptin, and log hs-CRP in all subjects (Table 3).

Furthermore, by multivariate linear regression analysis adjusted for confounding factors, TBR-A was significantly correlated with LDL-C (β = 0.001, p = 0.03) and log leptin (β = 0.336, p<0.01), as were age and sex, in all subjects (Table 4).

Discussion

By multivariate regression analysis adjusted for age and sex, we showed that TBR-A was significantly correlated with various clinical and laboratory parameters, such as BMI, log visceral fat area, LDL-C, log TG, log IRI, log HOMA-IR, log T-A and log-leptin. Furthermore, by multivariate linear regression analysis adjusted for confounding factors, we showed that LDL-C and log-leptin were significantly correlated with TBR-A.

Recent studies reported that 18F-FDG PET could be a useful tool for the measurement of vascular inflammation. Histological studies by Rudd et al. indicated that FDG accumulation was localized within the atherosclerotic plaques [18]. Tawakol et al. showed that FDG-PET imaging can determine the in vivo macrophage content of carotid plaques [19], while Tahara et al. showed strong FDG accumulation in the carotid artery in an atherosclerotic plaque lesion [20]. Further studies confirmed that FDG uptake by the carotid artery wall was associated with atherosclerotic markers in healthy individuals [26–28]. In this study, we showed that TBR-A was significantly associated with BMI, which is consistent with previous studies [20,27].

Univariate regression analysis revealed a significant relationship between TBR-A and leptin in both men and women, but not in all subjects. A greater serum leptin level has been reported in women than in men [29], which is consistent with our current study findings. These different profiles of leptin levels for men and women resulted in the non-significant correlation observed by univariate regression analysis between TBR-A and leptin in all subjects in the present study.

On the other hand, we first reported that TBR-A was significantly associated with leptin after adjusting for confounding factors. Hyperleptinemia in the general population is associated with atherosclerotic disease and their risk factors [10,12]. This may be partly explained by the fact that increased leptin leads to increased insulin resistance, homeostasis imbalance, and vascular inflammation [30]. Dubey et al. reported that leptin and hs-CRP were independent predictors for complex lesion morphology in unstable angina [31]. Leptin is reported to play an important role in the early stages of atherosclerosis development by initiating leukocyte and macrophage recruitment to the endothelial wall [10]. Schneiderman et al. also showed that neurologically symptomatic patients overexpress leptin mRNA and synthesize leptin protein in carotid plaque macrophages and smooth muscle cells. This induction might be activated by cytokines like TNF-α when these are available within the plaque and in the systemic circulation. Excessive synthesis of leptin within the plaque could have paracrine or autocrine effects that could lead to destabilization of the atherosclerotic lesion, resulting in embolic complications [32]. In combination with our results, these suggest that leptin is a biomarker of active plaque. We also found that TBR-A...
Table 1. Characteristics of the Study Population.

|                          | Men (n = 119) | Women (n = 92) | All (n = 211) | p    |
|-------------------------|--------------|----------------|--------------|------|
| Age (years)             | 54.4±8.9     | 56.5±10.9      | 55.3±9.9     | 0.38 |
| BMI (kg/m²)             | 24.1±3.0     | 22.2±3.0       | 23.3±1.2     | <0.01**|
| Waist circumference (cm)| 85.5±9.7     | 82.0±8.9       | 84.0±9.5     | 0.02**|
| Visceral fat area (cm²) | 116.4±36.4   | 79.6±29.4      | 100.4±38.1   | <0.01**|
| Systolic BP (mmHg)      | 124.2±12.7   | 117.3±12.6     | 121.2±13.1   | <0.01**|
| Diastolic BP (mmHg)     | 79.6±9.0     | 72.0±10.0      | 76.3±10.2    | <0.01**|
| FPG (mmol/L)            | 5.48±0.71    | 5.04±0.40      | 5.28±0.63    | <0.01**|
| HbA1c (NGSP) (%)        | 5.5±0.4      | 5.4±0.3        | 5.5±0.4      | 0.58 |
| LDL-C (mmol/L)          | 3.05±0.78    | 3.45±0.93      | 3.22±0.87    | <0.01**|
| HDL-C (mmol/L)          | 1.47±0.34    | 1.68±0.34      | 1.56±0.36    | <0.01**|
| TG (mmol/L)             | 1.29±0.74    | 0.97±0.41      | 1.15±0.64    | <0.01**|
| UA (µmol/L)             | 362.86±71.38 | 261.73±59.49   | 315.27±83.28 | <0.01**|
| Glu (µmol/L)            | 70.72±10.61  | 53.04±8.84     | 62.76±13.26  | <0.01**|
| eGFR (mL/min/1.73 m²)   | 81.3±14.0    | 81.5±14.5      | 81.4±14.2    | 0.63 |
| TBR-Aorta               | 1.74±0.39    | 1.54±0.20      | 1.65±0.33    | <0.01**|
| HOMA-IR                 | 1.18±0.99    | 0.85±0.51      | 1.03±0.83    | 0.04**|
| 1,5-AG (µmol/L)         | 138.28±61.53 | 115.14±46.91   | 127.93±56.65 | <0.01**|
| HMW-A (mg/L)            | 3.47±2.12    | 5.91±3.18      | 4.53±2.89    | <0.01**|
| T-A (mg/L)              | 8.4±3.5      | 13.3±5.9       | 10.6±5.3     | <0.01**|
| Leptin (µg/L)           | 2.97±1.83    | 5.68±3.05      | 4.15±2.78    | <0.01**|
| hs-CRP (nmol/L)         | 8.92±16.42   | 11.29±48.56    | 9.95±34.27   | <0.01**|
| Anti-hypertensive agents| 20.2%        | 19.8%          | 20.0%        | 0.94 |
| Anti-diabetic agents    | 4.2%         | 2.2%           | 3.3%         | 0.42 |
| Statin                  | 10.1%        | 6.6%           | 8.6%         | 0.37 |
| Lipid-lowering agents   | 14.3%        | 7.7%           | 11.4%        | 0.14 |
| Antiplatelet agents     | 8.4%         | 3.3%           | 6.2%         | 0.13 |
| Gout remedy             | 8.4%         | 0%             | 4.8%         | <0.01**|
| Smoking history         | none         | current smoke  | past smoke   | <0.01**|

**; p<0.01, *; p<0.05.

* body mass index, † blood pressure, ‡ fasting plasma glucose, § glycosylated hemoglobin A1c, ‖ uric acid, ¶ creatinine, ¶ estimated glomerular filtration rate, ‖ target-to-background ratio-ascending aorta, ‖ immunoreactive insulin, ‱ homeostasis model assessment of insulin resistance, ′ 1,5-anhydroglucitol, ′′ high-molecular-weight adiponectin, ′′′ total adiponectin, ′′′′ high sensitive C-reactive protein.

doi:10.1371/journal.pone.0111990.t001

is significantly correlated with LDL-C after adjusting for confounding factors. It is well known that high serum levels of LDL-C play a main role in the initiation and progression of atherosclerosis [33]. The nascent plaque progresses over time to form a raised lesion consisting of a fibrous layer of scar tissue overlying a lipid-rich core. These raised fibrous plaques then progress at a rate that is proportional to the circulating level of plasma LDL-C to ultimately form larger and more complex lesions, which continue to progress and can eventually become vulnerable to disruption [34,35]. Tahara et al. showed that LDL-C-lowering therapy with statin attenuates plaque inflammation evaluated by FDG-PET [36]. Further studies are needed to clarify the relationship between aortic 18F-FDG uptake and lipid metabolism.

Montecchi et al. reported that type 2 diabetes caused atherosclerosis at a more accelerated rate than hypercholesterolemia [37]. However, we could not find a significant relationship between TBR-A and markers related with glycometabolism such as HbA1c and HOMA-IR. This is probably because only 3.3% of the patients in this present study were diabetic, and the subjects whose HbA1c was >7% or whose glucose levels were higher than 11.10 mmol/L were excluded. It may be difficult to assess the influence of hyperglycemia to vascular inflammation by FDG-PET, since the FDG uptake rate in tissues is enhanced by high plasma glucose levels [38,39].

One interesting finding was that multivariate linear regression analysis of 152 of 211 subjects with no treatment for atherosclerosis at a more accelerated rate than hypercholesterolemia revealed a significant correlation between TBR-A and lipid metabolism with statin (β = 0.623, p<0.01), but not with LDL-C (β = 0,
### Table 2. Correlation Coefficients of the TBR-Aorta with Other Variables as Determined by Univariate Regression Analysis.

|                     | Men (n = 119) | Women (n = 92) | All (n = 211) |
|---------------------|--------------|---------------|--------------|
| **Age**             | -0.047       | 0.065         | -0.019       |
| **BMI**             | 0.264**      | 0.244*        | 0.318**      |
| Waist Circumference | 0.179        | 0.207*        | 0.224**      |
| Visceral Fat Area   | 0.125        | 0.204         | 0.235**      |
| Systolic BP         | -0.008       | -0.019        | 0.065        |
| Diastolic BP        | 0.098        | 0.056         | 0.196**      |
| FPG                 | 0.011        | 0.094         | 0.144*       |
| HbA1c               | 0.070        | -0.012        | 0.041        |
| LDL-C               | 0.168        | 0.151         | 0.090        |
| HDL-C               | 0.019        | -0.007        | -0.079       |
| TG                  | 0.145        | 0.044         | 0.165*       |
| UA                  | 0.218*       | 0.063         | 0.300**      |
| Cr                  | 0.111        | 0.189         | 0.276**      |
| eGFR                | -0.079       | -0.181        | -0.120       |
| IRI                 | 0.202*       | 0.209*        | 0.205**      |
| HOMA-IR             | 0.183*       | 0.214*        | 0.206**      |
| 1,5-AG              | -0.092       | 0.136         | 0.057        |
| HMW-A               | -0.129       | -0.179        | -0.265**     |
| T-A                 | -0.126       | -0.181        | -0.264**     |
| Leptin              | 0.244**      | 0.369**       | 0.078        |
| hs-CRP              | 0.149        | 0.106         | 0.176*       |

**; p<0.01, *; p<0.05.
doi:10.1371/journal.pone.0111990.t002

### Table 3. Multiple Linear Regression Analysis of TBR-Aorta Adjusted for Age and Sex in All Subjects.

|                      | β         | 95%CI       | p       |
|----------------------|-----------|-------------|---------|
| BMI                  | 0.036     | 0.022, 0.049| <0.01** |
| Waist Circumference  | 0.008     | 0.003, 0.013| <0.01** |
| log Visceral Fat Area| 0.440     | 0.140, 0.740| <0.01** |
| Systolic BP          | 0.001     | -0.003, 0.005| 0.52    |
| Diastolic BP         | 0.005     | 0.000, 0.009| <0.05*  |
| FPG                  | 0.002     | -0.002, 0.006| 0.34    |
| HbA1c                | 0.052     | -0.065, 0.169| 0.38    |
| LDL-C                | 0.002     | 0.001, 0.003| <0.01** |
| HDL-C                | 0.000     | -0.004, 0.003| 0.78    |
| log TG               | 0.300     | 0.088, 0.513| <0.01** |
| UA                   | 0.047     | 0.009, 0.085| 0.02*   |
| Cr                   | 0.431     | 0.030, 0.832| 0.04*   |
| eGFR                 | -0.003    | -0.007, 0.000| 0.06    |
| log IRI              | 0.099     | 0.003, 0.195| 0.04*   |
| log HOMA-IR          | 0.100     | 0.006, 0.194| 0.04*   |
| log 1,5-AG           | 0.010     | -0.076, 0.095| 0.82    |
| log HMW-A            | -0.130    | -0.302, 0.042| 0.14    |
| log T-A              | -0.242    | -0.482, -0.002| <0.05* |
| log leptin           | 0.357     | 0.196, 0.518| <0.01** |
| log hs-CRP           | 0.107     | 0.021, 0.194| 0.02*   |

**; p<0.01, *; p<0.05.
β: standardized regression coefficient.
95%CI: 95% confidence interval.
doi:10.1371/journal.pone.0111990.t003
p = 0.80). This may suggest that a general population with no treatment for atherosclerotic risk factors is less likely to have progressive atherosclerotic disease.

There are some limitations to this study. There may have been a selection bias, as individuals who participated in cancer screening by PET/CT were enrolled in the study. The sample size was relatively small, and other non-invasive methods for atherosclerosis, such as carotid intima-media thickness or ankle-brachial index, could not be evaluated. We were also unable to assess calcium scores because we obtained these images without cardiac gating and without the patients holding their breath. Further studies are needed to clarify the availability of aortic 18F-FDG uptake to patients and without cardiac gating and without the patients holding their breath. Further studies are needed to clarify the availability of aortic 18F-FDG uptake to clinical and laboratory findings related with atherosclerosis.

### Table 4. Multiple Linear Regression Analysis Adjusted by Confounding Factors.

|                      | β      | 95%CI          | p        |
|----------------------|--------|----------------|----------|
| Age                  | −0.005 | −0.010, 0.000  | 0.03*    |
| Sex                  | −0.360 | −0.390, −0.131 | <0.01**  |
| log Visceral Fat Area| 0.247  | −0.058, 0.553  | 0.11     |
| LDL-C                | 0.001  | 0.000, 0.003   | 0.03*    |
| log HOMA-IR          | −0.042 | −0.163, 0.080  | 0.50     |
| log leptin           | 0.336  | 0.112, 0.560   | <0.01**  |

**; p<0.01, *; p<0.05.

doi:10.1371/journal.pone.0111990.t004

In conclusion, TBR-A was significantly correlated with LDL-C and log-leptin, independent from confounding factors. Our results suggest that aortic 18F-FDG uptake is a good marker of atherosclerosis, even in a general population.

### Author Contributions

Conceived and designed the experiments: AH NH T, Kudo NT. Performed the experiments: AH T, Kamasaki IM TU. Analyzed the data: AH NH T, Kudo NT. Contributed reagents/materials/analysis tools: IM TU KC. Wrote the paper: AH NH TA NA KY KT T, Kudo AK NT.

**References**

1. Nabel EG (2003) Cardiovascular disease. N Engl J Med 349: 60–72.
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr., Clark LR, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44: 720–732.
3. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, et al. (2005) Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290: 886–894.
4. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115–126.
5. Nichols WW, Pepine CJ, O’Rourke MF (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke. N Engl J Med 340: 1762–1763.
6. Rodwell PM (2000) Carotid artery disease and the risk of ischemic stroke and coronary vascular events. Cerebrovasc Dis 10 Suppl 5: 21–33.
7. Pasternak G, Schonfeld AH, van der Wal AC, Haudenschild CC, Clariss RJ, et al. (1998) Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. J Am Coll Cardiol 32: 655–662.
8. Van de Voorde J, Vanwey B, Boydens C, Decaluwe H (2013) Adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 18: 313–325.
9. Ziegler J, Von Hatzfeldt B, Dieckmann C, Oschmann G, Krammer PH, et al. (2000) Positive correlation of the murine obesity gene and its human homologue. Nature 372: 425–428.
10. Matsubara HS, Rundevad HS (2013) Role of adipokines in cardiovascular disease. J Endocrinol 216: T17–36.
11. Lago F, Dieguez C, Gomez-Reino J, Gualillo O (2007) The emerging role of adipocytokines such as adiponectin and leptin in cardiovascular disease. Metabolism 62: 1513–1521.
12. Zabalegui FD, Pauwels B, Decaluwe K (2013) Adipocytokines in oncology. Radiology 231: 305–332.
13. Nabel EG (2003) Cardiovascular disease. N Engl J Med 349: 60–72.
14. Rudd JH, Myers KS, Bansilal S, Machac J, Ralluque A, et al. (2007) (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol 50: 892–896.
15. Ben-Haim S, Kupzov E, Tamir A, Israel O (2004) Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. J Nucl Med 45: 1816–1821.
16. Zheng H, Ali A (2002) 18-fluoro-deoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 32: 47–59.
17. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, et al. (2002) Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105: 2708–2711.
18. Tawakol A, Magrino RQ, Bhatnagar GG, Bedini S, Vermeyden D, et al. (2006) In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 48: 1818–1824.
19. Tahara N, Kaki H, Yamagishi S, Mizoguchi M, Nakaura H, et al. (2007) Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 49: 1533–1539.
20. Takamura N, Hayashi N, Hane K, Kadota K, Yamasaki H, et al. (2010) Leptin to high-molecular-weight adiponectin ratio is independently correlated with carotid intima-media thickness in men, but not in women. Biomarkers 15: 340–344.
21. National Kidney F (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1–S96.
22. Kamasaki T, Hayashi N, Miyamoto I, Utsi T, Chiba K, et al. (2014) PET/CT shows subjective pain in shoulder joints to be associated with uptake of [18F]-FDG. J Nucl Med Commun 35: 44–50.
23. Minami S, Suga K, Isokuma T, Furukawa M, Chiba K (2007) Detection of lymph node metastasis using PET/CT in cholangiocarcinoma. Acta Med Nagasaki 52: 59–61.
24. Chiba K, Isoda M, Chiba M, Kamemoto T, Eguichi S (2010) Significance of PET/CT in determining actual TNM staging for patients with various lung cancer. Int Surg 95: 197–201.
25. Yokoe T, Moon SH, Cho YS, Hong SP, Lee JY, et al. (2013) Relation of carotid artery 18F-FDG uptake to C-reactive protein and Framingham risk score in a large cohort of asymmetric adults. J Nucl Med 54: 2070–2076.
26. Yang SJ, Kim S, Choi HY, Kim TN, Yoo HJ, et al. (2013) High-sensitivity C-reactive protein in the low- and intermediate-Framingham risk score groups: analysis with 18F-fluorodeoxyglucose positron emission tomography. Int J Caroti 163: 277–281.
27. Yoo HJ, Kim S, Park MS, Yang SJ, Kim TN, et al. (2011) Vascular inflammation stratified by C-reactive protein and low-density lipoprotein cholesterol levels: analysis with 18F-FDG PET. J Nucl Med 52: 10–17.
29. Roemmich JN, Clark PA, Berr SS, Mai V, Mantzoros CS, et al. (1998) Gender differences in leptin levels during puberty are related to the subcutaneous fat depot and sex steroids. Am J Physiol 275: E543–551.

30. Wannamethee SG, Trichopoulou A, Whincup P, Lowe GD, Kelly A, et al. (2007) Plasma leptin associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis 191: 418–426.

31. Dubey L, Zeng H, Hashmi S, Hongjie W, Tao H (2008) Association of plasma leptin levels and complexity of the culprit lesion in patients with unstable angina. Int J Cardiol 126: 183–189.

32. Schneiderman J, Schaefer K, Kolodgie FD, Savion N, Kotev-Emeth S, et al. (2012) Leptin locally synthesized in carotid atherosclerotic plaques could be associated with lesion instability and cerebral emboli. J Am Heart Assoc 1: e001727.

33. Badimon L, Vilahur G (2012) LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. Ann N Y Acad Sci 1254: 18–32.

34. Libby P, Theroux P (2005) Pathophysiology of coronary artery disease. Circulation 111: 3481–3488.

35. Ference BA, Mahajan N (2013) The role of early LDL lowering to prevent the onset of atherosclerotic disease. Curr Atheroscler Rep 15: 312.

36. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, et al. (2006) Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 48: 1825–1831.

37. Montecchi FR, Menzinger G, Lala A (2003) Carotid intima-media thickness in patients with Type 2 diabetes and hypercholesterolemia. Diabetes Nutr Metab 14: 58–61.

38. Lindholm H, Brolin F, Jonsson C, Jacobsson H (2013) The relation between the blood glucose level and the FDG uptake of tissues at normal PET examinations. EJNMMI Res 3: 50.

39. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, et al. (1993) Influence of the blood glucose concentration on FDG uptake in cancer—a PET study. J Nucl Med 34: 1–6.